智通财经APP讯，兆科眼科-B(06622)公布，于2026年6月2日，澳洲Therapeutic Goods Administration(治疗用品管理局)已受理评核公司就其用于减慢儿童近视加深疗法的硫酸阿托品滴眼液(0.02%剂量，产品代码：NVK002)提出的注册申请。
治疗用品局已正式知会公司的申请已通过初步评审，将会进行评核。是项申请乃以公司进行的第III期临床试验所获得的支持性结果为基础。
硫酸阿托品滴眼液(NVK002)为一种用于减慢儿童及青少年近视加深的滴眼液。硫酸阿托品滴眼液(NVK002)乃一项专利配方，有效解决低浓度阿托品的不稳性。此技术在全球均受到知识产权保护。此滴眼液不含防腐剂，预计保存期为24个月。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.